ADC Manufacturing Facility
Courtesy of AstraZeneca
Singapore
AstraZeneca is planning to construct a US$1.5 billion facility in Singapore for the manufacture of antibody drug conjugates (ADCs). Enabling the creation of precision cancer therapies, the project will integrate every stage of the ADC production process at commercial scale. The sustainably designed building is slated to achieve net-zero operational carbon and will leverage advanced infrastructure to achieve optimal energy performance. Completion is expected in 2029. A site for the greenfield development has yet to be determined.
